45
Merck KGaA is to acquire Mirus Bio, a provider of transfection products for the biopharmaceutical and research industries, from Gamma Biosciences, a life sciences platform established by KKR to address the advanced therapy bioprocessing market, for US$600m in cash.
US-based Mirus Bio offers a comprehensive portfolio of RUO and GMP reagents and enhancers based on proprietary, multi-component technology. Its products deliver high-performance and cost-effective transfection for a variety of applications, from research through virus…